
USD
+$0.00
(+0.00%
)At Close (As of Oct 23, 2025)
$445.49M
Market Cap
-
P/E Ratio
-0.67
EPS
$5.77
52 Week High
$0.61
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.6M |
| Total Revenue | $3.1M |
| Cost Of Revenue | $1.5M |
| Costof Goods And Services Sold | $1.5M |
| Operating Income | -$109M |
| Selling General And Administrative | $51M |
| Research And Development | $60M |
| Operating Expenses | $110M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.6M |
| Income Before Tax | -$101M |
| Income Tax Expense | $56K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$101M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$109M |
| Ebitda | -$104M |
| Net Income | -$101M |
| Field | Value (USD) |
|---|---|
| Total Assets | $248M |
| Total Current Assets | $218M |
| Cash And Cash Equivalents At Carrying Value | $49M |
| Cash And Short Term Investments | $49M |
| Inventory | $4.1M |
| Current Net Receivables | $1.3M |
| Total Non Current Assets | $30M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $160M |
| Other Current Assets | $3M |
| Other Non Current Assets | - |
| Total Liabilities | $32M |
| Total Current Liabilities | $18M |
| Current Accounts Payable | $1.9M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $3.7M |
| Total Non Current Liabilities | $14M |
| Capital Lease Obligations | $13M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $13M |
| Other Current Liabilities | $11M |
| Other Non Current Liabilities | $19K |
| Total Shareholder Equity | $215M |
| Treasury Stock | - |
| Retained Earnings | -$597M |
| Common Stock | $18K |
| Common Stock Shares Outstanding | $143M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$88M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $4.6M |
| Capital Expenditures | $4.6M |
| Change In Receivables | - |
| Change In Inventory | $4.3M |
| Profit Loss | - |
| Cashflow From Investment | -$33M |
| Cashflow From Financing | $36M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$101M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $1.6M |
| Total Revenue | $3.1M |
| Cost Of Revenue | $1.5M |
| Costof Goods And Services Sold | $1.5M |
| Operating Income | -$109M |
| Selling General And Administrative | $51M |
| Research And Development | $60M |
| Operating Expenses | $110M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.6M |
| Income Before Tax | -$101M |
| Income Tax Expense | $56K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$101M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$109M |
| Ebitda | -$104M |
| Net Income | -$101M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Quantum-Si Inc. is a leading innovator in the biotechnology sector, specializing in a next-generation protein sequencing platform designed to revolutionize healthcare. By integrating cutting-edge technology, the company enhances proteomics research, offering valuable insights into protein structures and functions that are crucial for drug discovery and personalized medicine. Quantum-Si's approach seeks to overcome the limitations of traditional sequencing methods, positioning it to tackle significant challenges in genomics and ultimately drive advancements in healthcare outcomes and scientific understanding.